Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Multiple Sclerosis

Free Subscription Articles published in Lancet Retrieve available abstracts of 17 articles: HTML format Text format

Single Articles

March 2018
1. KAPPOS L, Bar-Or A, Cree BAC, Fox RJ, et al
   Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
   Lancet. 2018 Mar 22. pii: S0140-6736(18)30475.
   PubMed     Text format     Abstract available
   
   
   
2. THOMPSON AJ, Baranzini SE, Geurts J, Hemmer B, et al
   Multiple sclerosis.
   Lancet. 2018 Mar 22. pii: S0140-6736(18)30481.
   PubMed     Text format     Abstract available
   
   
   
3. THE LANCET
   End of the road for daclizumab in multiple sclerosis.
   Lancet. 2018;391:1000.
   PubMed     Text format    
   
   
   October 2017
4. GREEN AJ, Gelfand JM, Cree BA, Bevan C, et al
   Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.
   Lancet. 2017 Oct 10. pii: S0140-6736(17)32346.
   PubMed     Text format     Abstract available
   
   
   March 2017
5. ATKINS H, Freedman MS
   Immunoablation and aHSCT for aggressive multiple sclerosis - Authors' reply.
   Lancet. 2017;389:908.
   PubMed     Text format    
   
   
   
6. HARRIS M, Cossburn M, Gregory R
   Immunoablation and aHSCT for aggressive multiple sclerosis.
   Lancet. 2017;389:907-908.
   PubMed     Text format    
   
   
   January 2017
7. CHEN H, Kwong JC, Copes R, Tu K, et al
   Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study.
   Lancet. 2017 Jan 4. pii: S0140-6736(16)32399.
   PubMed     Text format     Abstract available
   
   
   November 2016
8. COMI G, Radaelli M, Soelberg Sorensen P
   Evolving concepts in the treatment of relapsing multiple sclerosis.
   Lancet. 2016 Nov 23. pii: S0140-6736(16)32388.
   PubMed     Text format     Abstract available
   
   
   
9. ONTANEDA D, Thompson AJ, Fox RJ, Cohen JA, et al
   Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.
   Lancet. 2016 Nov 23. pii: S0140-6736(16)31320.
   PubMed     Text format     Abstract available
   
   
   
10. BROWNLEE WJ, Hardy TA, Fazekas F, Miller DH, et al
    Diagnosis of multiple sclerosis: progress and challenges.
    Lancet. 2016 Nov 23. pii: S0140-6736(16)30959.
    PubMed     Text format     Abstract available
    
    
    June 2016
11. ATKINS HL, Bowman M, Allan D, Anstee G, et al
    Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
    Lancet. 2016 Jun 8. pii: S0140-6736(16)30169.
    PubMed     Text format     Abstract available
    
    
    
12. DORR J
    Haemopoietic stem-cell transplantation for multiple sclerosis: what next?
    Lancet. 2016 Jun 8. pii: S0140-6736(16)30377.
    PubMed     Text format    
    
    
    April 2016
13. SNYDER A
    John Kurtzke.
    Lancet. 2016;387:1370.
    PubMed     Text format    
    
    
    January 2016
14. SEGAL BM, Stuve O
    Primary progressive multiple sclerosis-why we are failing.
    Lancet. 2016 Jan 27. pii: S0140-6736(16)00158.
    PubMed     Text format    
    
    
    
15. LUBLIN F, Miller DH, Freedman MS, Cree BA, et al
    Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet. 2016 Jan 27. pii: S0140-6736(15)01314.
    PubMed     Text format     Abstract available
    
    
    September 2015
16. COMI G, Radaelli M
    Oral corticosteroids for multiple sclerosis relapse.
    Lancet. 2015;386:937-9.
    PubMed     Text format    
    
    
    June 2015
17. LE PAGE E, Veillard D, Laplaud DA, Hamonic S, et al
    Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
    Lancet. 2015 Jun 26. pii: S0140-6736(15)61137.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: